(December 3, 2019, 2:43 PM EST) -- PHILADELPHIA — The Pennsylvania Superior Court on Nov. 26 affirmed a $76.66 million compensatory verdict in a Risperdal gynecomastia case, in part because defendants Janssen Pharmaceuticals Inc. allegedly concealed a study that found a statistically significant risk (A.Y., et al. v. Janssen Pharmaceuticals Inc., et al., Nos. 3058 EDA 2016 and 3059 EDA 2016, Pa. Super.)....